Robert Dreicer, MD, MS, MACP, FASCO: Advanced urothelial cancer, after decades of really no progress at all, has exploded like a lot of other areas in oncology. All we had for 25 or 30 years was platinum-based chemotherapy. We’ve seen multiple checkpoint inhibitors approved that have impacted the natural history of the disease, and some have dramatically changed what happens to people. Again, the challenge with checkpoint inhibitors is they still only impact 1 of 5 patients. But all of us who manage this disease have patients who are multiple years out. They may not be cured, but they also may not die of urothelial cancer. So progress has been made.
Recent approvals of erdafitinib for FGFR2- and FGFR3-mutated patients, and enfortumab vedotin, have been badly needed for second- and third-line therapy.
There have been some setbacks with the frontline trials of checkpoint inhibitors plus chemotherapy. The adjuvant study of atezolizumab was also negative. But there are a lot of exciting combinations in the pipeline. There are some very intriguing data on the combination of enfortumab vedotin with pembrolizumab. We’ve seen that data, in terms of phase 2 experiences.
We’ve also seen other checkpoint inhibitor approvals: Pembrolizumab for BCG [Bacillus Calmette-Guerin]–unresponsive, high-grade, T1 nonmuscle-invasive disease with carcinoma in situ. That’s also very exciting.
There are very compelling data on the use of checkpoint inhibitors in the neoadjuvant setting. There are a range of studies, including enfortumab plus checkpoint novel FGFR agents that are moving into the neoadjuvant setting. Upper-tract disease highly enriched with FGFR mutations. Also, FGFR agents moving into those settings.
So this is a really exciting time in urothelial cancer. There are a lot of trials, including another CTLA4-plus-checkpoint-inhibitor study. We know of the enfortumab up-front trials. This is a very intriguing time. There are lots of moving parts. There is probably no defined sequence right now. There are multiple sequences we can use. Although we’d like to have definitive data about everything, we have multiple agents moving in with new combinations that are going to be reporting. It’s a pretty exciting time for those of us who manage this disease state.
Transcript edited for clarity.
Case: A 65-Year-Old Female With Urothelial Carcinoma
Initial presentation
Clinical workup
Treatment
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More